Arteaus Therapeutics takes on Lilly’s migraine compound; Lilly later regains rights
Specialty pharma start-up Arteaus Therapeutics LLC has licensed worldwide rights to develop one of Eli Lilly & Co.’s early-stage migraine prevention compounds.
- Specialty Pharmaceuticals
- Large Molecule
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.